LOGO
LOGO

Deep B-Cell Depletion: The Next Wave In Autoimmune Diseases With Artiva's AlloNK In Focus

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
happyinvestors 24042026 lt

Shares of Artiva Biotherapeutics Inc. (ARTV) have more than doubled year-to-date, driven by continued progress in its lead AlloNK program.

AlloNK is an off-the-shelf cell therapy made from donor immune cells (NK cells) that are frozen and stored until needed. It helps antibody drugs work better by boosting their ability to drive deep B-cell depletion.

Deep B-cell depletion mechanism of action represents potential to address limitations of existing therapies by providing durable clinical improvement.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.